Fusion protein · Immune activation · developed by Xencor
XmAb662 is an engineered, potency-reduced fusion protein of human interleukin-12 (IL-12) and an Fc domain. IL-12 activates CD8+ and CD4+ T-cells and natural killer cells, promoting interferon-gamma secretion and cytolytic immune responses. It is being studied in solid tumors, and the Fc domain prolongs its half-life and exposure in the tumor.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05996445 | Phase 1 | Solid Tumors | Terminated | XNCR |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Solid Tumors
Updated Nov 1, 2026. Something wrong or missing? Report it on the XNCR page.
See XNCR's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
XNCR catalysts and pipeline →